Over 300 Total Lots Up For Auction at Two Locations - Jutland 12/13, MD 12/14

Whiterabbit.ai signs national distribution agreement with Arterys to expand reach of its AI-powered early cancer detection tech

Press releases may be edited for formatting or style | August 24, 2022 Artificial Intelligence Health IT Women's Health
SANTA CLARA, Calif.--(BUSINESS WIRE)--Whiterabbit.ai, an AI-technology company dedicated to making late-stage diseases a rarity, today announced it signed a national distribution agreement with Arterys, a San Francisco-based AI-powered software company and developer of the world’s first internet platform for medical imaging, to expand the reach of Whiterabbit’s AI-driven software program ACT, nationwide. The program is designed to increase mammography screening compliance and volume.

Arterys’ broad customer base of healthcare systems, some of which use its Breast AI software to detect breast cancer, measure breast density and deliver personalized risk assessments, will be able to purchase and integrate ACT into their compliance screening programs. Increasing the number of women who schedule their annual mammograms is essential to detecting cancer earlier. The partnership has the potential to significantly reduce the backlog of preventive screenings that were missed and remain overdue as a result of the COVID-19 pandemic.

“Our strategic partnership with Arterys further anchors Whiterabbit’s mission to make late-stage diseases a rarity through increased accessibility, supported by innovative AI-powered software,” said Whiterabbit.ai CEO Alexander Sardiña, MD. “We believe AI has the power to transform healthcare through compliance, accurate disease detection and a patient-centric approach at cost reduction.”

“Arterys is extremely pleased to add Whiterabbit’s AI ACT solution to our current suite of breast AI applications,” said Dan Arnoff, senior VP of commercialization at Arterys. “ACT drives the compliance of screening mammograms, which in turn potentially reduces interval cancers. ACT combined with our current Breast AI solution for tomosynthesis provides the end user a very unique platform in the fight against breast cancer. Arterys is committed to developing the best of class AI solutions, deployed from a single cloud interface to maximize the power of AI to breast centers across the globe.”

According to leading organizations dedicated to breast cancer research and education, it is estimated more than 287,800 women will be diagnosed with invasive breast cancer and more than 43,000 will die from breast cancer in 2022 in the U.S. Whiterabbit and Arterys are dedicated to transforming healthcare through the intersection of human intelligence and artificial intelligence to improve clinical outcomes for patients.

You Must Be Logged In To Post A Comment